Department of Urology, San Giovanni Battista Hospital, Città della Salute e della Scienza and University of Turin, Turin, Italy.
Department of, Urology, Drum Tower Hospital, Medical School of Nanjing University, Nanjing University, Nanjing, Jiangsu, China.
BJU Int. 2021 Jan;127(1):122-130. doi: 10.1111/bju.15121. Epub 2020 Aug 2.
To assess the outcomes of multiparametric magnetic resonance imaging (mpMRI) transperineal targeted fusion biopsy (TPFBx) under local anaesthesia.
We prospectively screened 1327 patients with a positive mpMRI undergoing TPFBx (targeted cores and systematic cores) under local anaesthesia, at two tertiary referral institutions, between September 2016 and May 2019, for inclusion in the present study. Primary outcomes were detection of clinically significant prostate cancer (csPCa) defined as (1) International Society of Urological Pathologists (ISUP) grade >1 or ISUP grade 1 with >50% involvement of prostate cancer (PCa) in a single core or in >2 cores (D1) and (2) ISUP grade >1 PCa (D2). Secondary outcomes were: assessment of peri-procedural pain (numerical rating scale [NRS]) and procedure timings; erectile (International Index of Erectile Function) and urinary (International Prostate Symptom Score) function changes; and complications. We also investigated the value of systematic sampling and concordance with radical prostatectomy (RP).
A total of 1014 patients were included, of whom csPCa was diagnosed in 39.4% (n = 400). The procedure was tolerable (NRS pain score 3.1 ± 2.3), with no impact on erectile (P = 0.45) or urinary (P = 0.58) function, and a low rate of complications (Clavien-Dindo grades 1 or 2, n = 8; grade >2, n = 0). No post-biopsy sepsis was recorded. Twenty-two men (95% confidence interval [CI] 17-29) needed to undergo additional systematic biopsy to diagnose one csPCa missed by targeted biopsies (D1). ISUP grade concordance of biopsies with RP was as follows: k = 0.40 (95% CI 0.31-0.49) for targeted cores alone and k = 0.65 (95% CI 0.57-0.72; P < 0.05) overall.
The use of TPFBx under local anaesthesia yielded good csPCa detection and was feasible, quick, well tolerated and safe. Infectious risk was negligible. Addition of systematic to targeted cores may not be needed in all men, although it improves csPCa detection and concordance with RP.
评估局部麻醉下经会阴多参数磁共振成像(mpMRI)靶向融合活检(TPFBx)的结果。
我们前瞻性筛选了 2016 年 9 月至 2019 年 5 月期间在两家三级转诊机构接受局部麻醉下 TPFBx(靶向核心和系统核心)的 1327 名阳性 mpMRI 患者,纳入本研究。主要结局是检测临床显著前列腺癌(csPCa),定义为(1)国际泌尿病理学家协会(ISUP)分级>1 或 ISUP 分级 1 伴前列腺癌(PCa)在单个核心或>2 个核心中(D1)的>50%累及和(2)ISUP 分级>1 PCa(D2)。次要结局是:评估围手术期疼痛(数字评分量表[NRS])和手术时间;勃起(国际勃起功能指数)和尿功能(国际前列腺症状评分)的变化;以及并发症。我们还研究了系统抽样的价值以及与根治性前列腺切除术(RP)的一致性。
共纳入 1014 例患者,其中 39.4%(n=400)诊断为 csPCa。该手术耐受良好(NRS 疼痛评分 3.1±2.3),对勃起功能(P=0.45)或尿功能(P=0.58)无影响,并发症发生率低(Clavien-Dindo 分级 1 或 2,n=8;分级>2,n=0)。未记录活检后脓毒症。22 名男性(95%置信区间[CI]17-29)需要接受额外的系统活检,以诊断靶向活检遗漏的 1 例 csPCa(D1)。与 RP 相比,活检的 ISUP 分级一致性如下:仅靶向核心的 k=0.40(95%CI 0.31-0.49)和整体 k=0.65(95%CI 0.57-0.72;P<0.05)。
局部麻醉下使用 TPFBx 可获得良好的 csPCa 检出率,且具有可行性、快速、可耐受和安全。感染风险可以忽略不计。虽然添加系统核心可能会提高 csPCa 的检出率和与 RP 的一致性,但并非所有男性都需要进行。